ID   HCC1954-LR
AC   CVCL_LG20
DR   cancercelllines; CVCL_LG20
DR   Wikidata; Q54881621
RX   PubMed=24876102;
CC   Population: East Indian.
CC   Selected for resistance to: ChEBI; CHEBI_49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene fusion; HGNC; HGNC:2092; CLTC + HGNC; HGNC:29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4017; Breast ductal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1259 ! HCC1954
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 19-12-24; Version: 13
//
RX   PubMed=24876102; DOI=10.1158/0008-5472.CAN-13-2053;
RA   Rani, Sweta
RA   Corcoran, Claire
RA   Shiels, Liam
RA   Germano, Serena
RA   Breslin, Susan
RA   Madden, Stephen F.
RA   McDermott, Martina S.
RA   Browne, Brigid C.
RA   O'Donovan, Norma
RA   Crown, John
RA   Gogarty, Martina
RA   Byrne, Annette Therese
RA   O'Driscoll, Lorraine
RT   "Neuromedin U: a candidate biomarker and therapeutic target to predict
RT   and overcome resistance to HER-tyrosine kinase inhibitors.";
RL   Cancer Res. 74:3821-3833(2014).
//